Summary

Market Size & Trends

The Middle East gastric cancer diagnostics market size was estimated at USD 25.68 million in 2024 and is projected to reach USD 48.04 million by 2033, growing at a CAGR of 7.32% from 2025 to 2033. Growth in the gastric cancer diagnostics market in the Middle East is driven by rising disease burden and delayed detection rates, which are fueling demand for early screening and molecular testing. Strategic initiatives such as Mylab-AstraGene’s 2023 partnership in the UAE and Kuwait, Guardant Health-Hikma’s 2024 collaboration to expand liquid biopsy access, and the UAE’s 2025 approval of Biomerica’s Fortel H. pylori test are enhancing diagnostic capacity. In addition, biomarker adoption, including Claudin 18.2 testing at Burjeel Medical City in 2025, underscores increasing precision oncology integration

The gastric cancer diagnostics market in the Middle East is entering a period of accelerated growth, supported by significant regulatory approvals, commercial partnerships, and increasing healthcare investment. Although the overall incidence of gastric cancer in the region is lower compared to East Asia, late detection and limited survival rates are creating strong demand for early diagnostic solutions and precision oncology. Recent developments highlight how the market is evolving across screening, molecular diagnostics, and companion testing.

A major milestone came in March, 2023, when Mylab Discovery Solutions partnered with AstraGene in the UAE and Kuwait. This collaboration focuses on the co-development of automated molecular diagnostic solutions, including reagents, kits, and fully automated platforms. The initiative is expected to reduce reliance on imports, improve affordability, and build local capacity to meet the rising demand for oncology testing. Localized manufacturing also ensures compliance with regional regulatory frameworks and supports hospitals and laboratories with faster access to advanced molecular technologies.

Middle East Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the Middle East gastric cancer diagnostics market report based on product, disease, end use, and country:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents & Consumables
• Instruments
• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Adenocarcinoma
• Gastric lymphoma
• Others
• End-Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Diagnostic Imaging
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• Middle East
o South Africa
o UAE
o Kuwait
o Oman
o Qatar

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Disease outlook
2.2.3. End Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. ME Gastric Cancer Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. ME Gastric Cancer Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. ME Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. ME Gastric Cancer Diagnostics Market: Product Movement Analysis
4.4. ME Gastric Cancer Diagnostics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.5. ME Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Reagents & consumables
4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Instruments
4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. ME Gastric Cancer Diagnostics Market: Disease Estimates & Trend Analysis
5.1. Disease Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. ME Gastric Cancer Diagnostics Market by Disease Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Adenocarcinoma
5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Gastric lymphoma
5.6.1. Gastric lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Others
5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. ME Gastric Cancer Diagnostics Market: End Use Estimates & Trend Analysis
6.1. End Use Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. ME Gastric Cancer Diagnostics Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Hospitals
6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Diagnostic Imaging
6.7.1. Diagnostic Imaging Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. ME Gastric Cancer Diagnostics Market: Country Estimates & Trend Analysis
7.1. Country Market Share Analysis, 2024 & 2033
7.2. Country Market Dashboard
7.3. Country Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.5. ME
7.5.1. Saudi Arabia
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/Reimbursement
7.5.1.3. Competitive scenario
7.5.1.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.5.2. UAE
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/Reimbursement
7.5.2.3. Competitive scenario
7.5.2.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. Kuwait
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. Oman
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/Reimbursement
7.5.4.3. Competitive scenario
7.5.4.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
7.5.5. Qatar
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/Reimbursement
7.5.5.3. Competitive scenario
7.5.5.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. MiRXES Pte Ltd.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Agilent Technologies Inc
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Endofotonics Pte Ltd
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Bio-Rad Laboratories, Inc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Hipro Biotechnology Co.,Ltd
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Exact Sciences Corporation
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. QIAGEN
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Fulgent Genetics.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. F. Hoffmann-La Roche Ltd
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Abbott
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives